Cover Image
市場調查報告書

慢性突發性便秘 (CIC)的全球市場的未來預測

GLOBAL CHRONIC IDIOPATHIC CONSTIPATION DRUG MARKET FORECAST 2017-2025

出版商 Inkwood Research 商品編碼 530654
出版日期 內容資訊 英文 128 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
慢性突發性便秘 (CIC)的全球市場的未來預測 GLOBAL CHRONIC IDIOPATHIC CONSTIPATION DRUG MARKET FORECAST 2017-2025
出版日期: 2017年07月19日 內容資訊: 英文 128 Pages
簡介

本報告提供全球慢性突發性便秘 (CIC) 治療藥的市場未來展望相關分析,疾病概要和市場基本結構、背景情況,主要的促進、阻礙因素,市場整體及各產品種類、各供給方法、各地區的市場趨勢預測 (今後9年份),主要企業簡介等調查。

第1章 分析範圍

第2章 分析方法

第3章 摘要整理

第4章 市場概要

  • 市場定義
  • 市場概要
  • 有前途的投資方案
  • 主要企業的市場上的定位
  • 市場的推動要素
  • 市場的阻礙要素
  • 市場機會
  • 課題

第5章 全球CIC治療藥市場:醫各類型藥品 (今後9年份,以金額為準)

  • 概要
  • 開發平台醫藥品分析 (第三階段):Plecanatide (2022年上市預定)
  • 開發平台醫藥品分析 (第三階段):ELOBIXIBAT (2022年上市預定)

第6章 全球CIC治療藥市場:各供給方法 (今後9年份,以金額為準)

  • 處方藥
  • OTC (成藥)

第7章 主要指標

  • 波特的五力分析
  • 供應商環境
  • 市場機會矩陣

第8章 全球CIC治療藥市場:各地區 (今後9年份,以金額為準)

  • 北美 (美國,加拿大)
  • 歐洲 (英國,德國等)
  • 亞太地區 (中國,日本等)
  • 其他的國家 (RoW:中東、非洲,南美)

第9章 企業簡介

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 6396

KEY FINDINGS

Global Chronic Idiopathic Constipation drug market is estimated to grow at a CAGR of 6.43% during the forecast period of 2017-2025. The important drivers propelling the market growth are the modern dietary habits, rising elderly population and the improved and efficient drugs in the pipeline. Linaclotide is the major type of drug popular in this market.

MARKET INSIGHT

The CIC drug market is segmented based on drug types and also on the basis of prescription types. The drug types segment includes:

Linaclotide

Lubiprostone

Others

The prescription type segment is further divided into:

Over the Counter drugs

Prescribed drugs

An increasing demand for CIC drug from Asia-Pacific market coupled with the high unmet needs globally is providing the market with plenty of growth opportunities.

REGIONAL INSIGHTS

Geographically, the global CIC drug market is segmented into the following regions:

North America - U.S. & Canada

Asia Pacific - China, Japan, and RoAPAC

Europe - UK, Germany, and RoE

Rest of World - MENA and Latin America

The North America is touted to account for the largest share during the forecast period on account of its developed healthcare systems and medical devices industry. Approximately 28% of the population residing there suffer from CIC. The growing government initiatives to treat and improve the healthcare segment of the society by providing latest technological and advance medical treatments are also aiding the market growth.

COMPETITIVE INSIGHTS

Advanced product launch is the key strategy adopted by the various market players of global CIC drug market. The other strategies include acquisition and mergers. For example, Roche holding Inc acquired Ariosa Diagnostics Inc, which provides non-invasive prenatal testing (NIPT) service using cell free DNA (cf-DNA) technology. Also, Allergan announced a collaboration with the company AstraZeneca in order to develop and commercialize ATM-AVI (aztreonam and avibactam) for antibiotic-resistant gram-negative infections. The other major players in the market include Synergy Pharmaceuticals, GlaxoSmithKline, Sucampo Pharmaceuticals Inc, Pfizer, Ironwood Pharmaceuticals Inc, etc.

1. RESEARCH SCOPE

  • 1.1. STUDY GOALS
  • 1.2. SCOPE OF THE MARKET STUDY
  • 1.3. WHO WILL FIND THIS REPORT USEFUL?
  • 1.4. STUDY AND FORECASTING YEARS

2. RESEARCH METHODOLOGY

  • 2.1. SOURCES OF DATA
    • 2.1.1. SECONDARY DATA
    • 2.1.2. PRIMARY DATA
  • 2.2. TOP DOWN APPROACH
  • 2.3. BOTTOM UP APPROACH
  • 2.4. DATA TRIANGULATION

3. EXECUTIVE SUMMARY

  • 3.1. MARKET SUMMARY

4. MARKET OVERVIEW

  • 4.1. MARKET DEFINITION
  • 4.2. KEY MARKET INSIGHTS
  • 4.3. ATTRACTIVE INVESTMENT SCENARIO
  • 4.4. POSITIONING OF KEY CIC DRUGS MANUFACTURERS IN THE MARKET
  • 4.5. MARKET DRIVERS
    • 4.5.1. MODERN DIETARY HABITS TAKING TOLL ON THE HEALTH
    • 4.5.2. CANCER OR OTHER SYSTEMATIC DISEASE CAN LEAD TO CIC
    • 4.5.3. INCREASING ELDERLY POPULATION
    • 4.5.4. IMPROVED AND EFFICIENT DRUGS IN PIPELINE
    • 4.5.5. INCREASING CONSTIPATION PROBLEMS DUE TO SIDE EFFECTS OF PRESCRIBED MEDICINES
  • 4.6. RESTRAINTS
    • 4.6.1. SURGICAL TREATMENTS
    • 4.6.2. UNAWARENESS AND IGNORANCE AMONG PEOPLE
  • 4.7. OPPORTUNITIES
    • 4.7.1. INCREASING DEMAND FOR CIC DRUG FROM APAC MARKET
    • 4.7.2. HIGH UNMET NEEDS
  • 4.8. CHALLENGES
    • 4.8.1. SIDE EFFECTS OF CIC DRUGS

5. GLOBAL CIC DRUGS MARKET, BY DRUG TYPE 2017-2025 ($ MILLION)

  • 5.1. OVERVIEW
    • 5.1.1. LUBIPROSTONE
    • 5.1.2. LINACLOTIDE
    • 5.1.3. OTHERS
  • 5.2. PIPELINE DRUG ANALYSIS: PHASE 3: PLECANATIDE (YEAR OF LAUNCH 2022, $ MILLION)
  • 5.3. PIPELINE DRUG ANALYSIS: PHASE 3: ELOBIXIBAT (YEAR OF LAUNCH 2022, $ MILLION)

6. GLOBAL CIC DRUGS MARKET BY PRESCRIPTION TYPE 2017-2025 ($ MILLION)

  • 6.1. PRESCRIBED DRUGS
  • 6.2. OVER THE COUNTER DRUGS

7. KEY ANALYTICS

  • 7.1. PORTERS FIVE FORCE ANALYSIS
    • 7.1.1. INTENSITY OF COMPETITIVE RIVALRY
    • 7.1.2. BARGAINING POWER OF SUPPLIER
    • 7.1.3. BARGAINING POWER OF BUYERS
    • 7.1.4. THREAT OF SUBSTITUTE PRODUCTS
    • 7.1.5. THREAT OF NEW ENTRANTS
  • 7.2. VENDOR LANDSCAPE
  • 7.3. OPPORTUNITY MATRIX

8. GLOBAL CIC DRUGS MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)

  • 8.1. NORTH AMERICA
    • 8.1.1. US
    • 8.1.2. CANADA
  • 8.2. EUROPE
    • 8.2.1. UK
    • 8.2.2. GERMANY
    • 8.2.3. REST OF EUROPE
  • 8.3. ASIA PACIFIC
    • 8.3.1. CHINA
    • 8.3.2. JAPAN
    • 8.3.3. REST OF ASIA PACIFIC
  • 8.4. REST OF THE WORLD
    • 8.4.1. MIDDLE EAST AND AFRICA
    • 8.4.2. LATIN AMERICA

9. COMPANY PROFILES

  • 9.1. ALLERGENS
    • 9.1.1. OVERVIEW
    • 9.1.2. PRODUCT PORTFOLIO
    • 9.1.3. STRATEGIC MOVES
    • 9.1.4. SCOT ANALYSIS
  • 9.2. CHUGAI PHARMACEUTICAL
    • 9.2.1. OVERVIEW
    • 9.2.2. PRODUCTS PORTFOLIO
    • 9.2.3. STRATEGIC MOVES
    • 9.2.4. SCOT ANALYSIS
  • 9.3. FERRING INTERNATIONAL CENTER S.A.
    • 9.3.1. OVERVIEW
    • 9.3.2. PRODUCTS PORTFOLIO
    • 9.3.3. SCOT ANALYSIS
  • 9.4. SYNERGY PHARMACEUTICALS
    • 9.4.1. OVERVIEW
    • 9.4.2. PRODUCTS PORTFOLIO
    • 9.4.3. SCOT ANALYSIS
  • 9.5. PFIZER
    • 9.5.1. OVERVIEW
    • 9.5.2. PFIZER PRODUCT PORTFOLIO
    • 9.5.3. SCOT ANALYSIS
  • 9.6. GLAXOSMITHKLINE
    • 9.6.1. OVERVIEW
    • 9.6.2. PRODUCT PORTFOLIO
    • 9.6.3. SCOT ANALYSIS
  • 9.7. ROCHE HOLDING AG
    • 9.7.1. OVERVIEW
    • 9.7.2. PRODUCT PORTFOLIO
    • 9.7.3. STRATEGIC MOVES
    • 9.7.4. SCOT ANALYSIS
  • 9.8. SANOFI
    • 9.8.1. OVERVIEW
    • 9.8.2. PRODUCTS PORTFOLIO
    • 9.8.3. SCOT ANALYSIS
  • 9.9. BAYER AG
    • 9.9.1. OVERVIEW
    • 9.9.2. PRODUCTS PORTFOLIO
    • 9.9.3. SCOT ANALYSIS
  • 9.10. MERCK SHARP & DOHME
    • 9.10.1. OVERVIEW
    • 9.10.2. PRODUCT PORTFOLIO
    • 9.10.3. SCOT ANALYSIS
  • 9.11. ELI LILLY AND COMPANY
    • 9.11.1. OVERVIEW
    • 9.11.2. PRODUCT PORTFOLIO
    • 9.11.3. SCOT ANALYSIS
  • 9.12. SALIX PHARMACEUTICALS LTD
    • 9.12.1. OVERVIEW
    • 9.12.2. PRODUCT PORTFOLIO
    • 9.12.3. SCOT ANALYSIS
  • 9.13. SUCAMPO PHARMACEUTICALS INC
    • 9.13.1. OVERVIEW
    • 9.13.2. PRODUCT PORTFOLIO
    • 9.13.3. SCOT ANALYSIS
  • 9.14. IRONWOOD PHARMACEUTICALS INC
    • 9.14.1. OVERVIEW
    • 9.14.2. PRODUCT PORTFOLIO
    • 9.14.3. SCOT ANALYSIS
  • 9.15. VALEANT PHARMACEUTICALS INTERNATIONAL
    • 9.15.1. OVERVIEW
  • 9.16. DAIICHI SANKYO CO LTD
    • 9.16.1. OVERVIEW
    • 9.16.2. PRODUCT PORTFOLIO
    • 9.16.3. SCOT ANALYSIS
  • 9.17. COSMO PHARMACEUTICALS SA
    • 9.17.1. OVERVIEW
    • 9.17.2. PRODUCT PORTFOLIO
    • 9.17.3. SCOT ANALYSIS
  • 9.18. PROGENICS PHARMACEUTICALS INC
    • 9.18.1. OVERVIEW
    • 9.18.2. PRODUCT PORTFOLIO
    • 9.18.3. SCOT ANALYSIS
  • 9.19. THERAVANCE BIOPHARMA INC
    • 9.19.1. OVERVIEW
    • 9.19.2. PRODUCT PORTFOLIO
    • 9.19.3. SCOT ANALYSIS

TABLES LIST

TABLE 1 GLOBAL CIC DRUG MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)

TABLE 2 PROMINENT DRUGS AND THEIR RESPECTIVE COMPANIES IN THERAPEUTICS FOR CHRONIC CONSTIPATION

TABLE 3 CONSTIPATION IN PARKINSON'S DISEASE

TABLE 4 COMMON MEDICINES CAUSING CONSTIPATION

TABLE 5 GLOBAL CIC DRUGS MARKET BY DRUG TYPE 2014-2022($ MILLION)

TABLE 6 PRODUCT PROFILE (LUBIPROSTONE)

TABLE 7 LUBIPROSTONE DRUG MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)

TABLE 8 PRODUCT PROFILE (LINACLOTIDE)

TABLE 9 LINACLOTIDE DRUG MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)

TABLE 10 PRODUCT PROFILE (BISACODYL)

TABLE 11 OTHERS DRUG MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)

TABLE 12 PIPELINE PRODUCT PROFILE (PLECANATIDE)

TABLE 13 PIPELINE PRODUCT PROFILE (ELOBIXIBAT)

TABLE 14 GLOBAL CIC DRUGS MARKET BY PRESCRIPTION TYPE 2017-2025 ($ MILLION)

TABLE 15 GLOBAL PRESCRIBED CIC DRUGS MARKET, BY GEOGRAPHY 2017-2025 ($ MILLION)

TABLE 16 LINZESS PRECAUTIONS AND SIDE EFFECTS

TABLE 17 GLOBAL OVER THE COUNTER CIC DRUG MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)

TABLE 18 NORTH AMERICA CIC DRUGS MARKET BY COUNTRY 2017-2025 ($ MILLION)

TABLE 19 U.S. CIC DRUGS MARKET BY PRESCRIPTION TYPE 2017-2025 ($ MILLION)

TABLE 20 U.S. CIC DRUGS MARKET BY MAJOR DRUGS 2017-2025 ($ MILLION)

TABLE 21 CANADA CIC DRUGS MARKET BY PRESCRIPTION TYPE 2017-2025 ($ MILLION)

TABLE 22 CANADA CIC DRUGS MARKET BY MAJOR DRUGS 2017-2025 ($ MILLION)

TABLE 23 EUROPE CIC DRUGS MARKET BY COUNTRY 2017-2025 ($ MILLION)

TABLE 24 UK CIC DRUGS MARKET BY PRESCRIPTION TYPE 2017-2025 ($ MILLION)

TABLE 25 UK CIC DRUGS MARKET BY MAJOR DRUGS 2017-2025 ($ MILLION)

TABLE 26 GERMANY CIC DRUGS MARKET BY PRESCRIPTION TYPE 2017-2025 ($ MILLION)

TABLE 27 GERMANY CIC DRUGS MARKET BY MAJOR DRUGS 2017-2025 ($ MILLION)

TABLE 28 ASIA PACIFIC CIC DRUGS MARKET BY COUNTRY 2017-2025 ($ MILLION)

TABLE 29 CHINA CIC DRUG MARKET BY PRESCRIPTION TYPE 2017-2025 ($ MILLION)

TABLE 30 CHINA CIC DRUG MARKET BY MAJOR DRUGS 2017-2025 ($ MILLION)

TABLE 31 JAPAN CIC DRUG MARKET BY PRESCRIPTION TYPE 2017-2025 ($ MILLION)

TABLE 32 JAPAN CIC DRUG MARKET BY MAJOR DRUGS 2017-2025 ($ MILLION)

TABLE 33 REST OF WORLD CIC DRUGS MARKET, BY REGION, 2017-2025 ($ MILLION)

TABLE 34 MENA CIC DRUG MARKET BY PRESCRIPTION TYPE 2017-2025 ($ MILLION)

TABLE 35 MENA CIC DRUG MARKET BY MAJOR DRUGS 2017-2025 ($ MILLION)

TABLE 36 LATIN AMERICA CIC DRUG MARKET BY PRESCRIPTION TYPE 2017-2025 ($ MILLION)

TABLE 37 LATIN AMERICA CIC DRUG MARKET BY MAJOR DRUGS 2017-2025 ($ MILLION)

FIGURE LIST

FIGURE 1 GLOBAL CHRONIC IDIOPATHIC CONSTIPATION (CIC) DRUG MARKET 2017-2025 ($ MILLION)

FIGURE 2 GLOBAL CIC DRUG MARKET BY DRUG TYPE 2017-2025 ($ MILLION)

FIGURE 3 GLOBAL CIC DRUG MARKET BY PRESCRIPTION TYPE IN 2016 ($ MILLION)

FIGURE 4 CAUSES OF CONSTIPATION

FIGURE 5 PROPORTION OF POPULATION AGED 60 OR ABOVE IN 2014

FIGURE 6 MAJOR CAUSES OF CONSTIPATION IN ELDERLY PEOPLE

FIGURE 7 EFFECTIVE DRUGS TO CREATE HUGE MARKET BENEFITS

FIGURE 8 SURGICAL OPTIONS AVAILABLE FOR CONSTIPATION

FIGURE 9 NEED OF SURGERY PROCESS

FIGURE 10 APAC CIC MARKET 2017-2025 ($ MILLION)

FIGURE 11 COMMON CONSTIPATION DRUGS AND SIDE EFFECTS CAUSED DUE TO THEM

FIGURE 12 GLOBAL LUBIPROSTONE DRUG MARKET 2017-2025 ($ MILLION)

FIGURE 13 GLOBAL LINACLOTIDE DRUG MARKET 2017-2025 ($ MILLION)

FIGURE 14 GLOBAL OTHER DRUGS MARKET 2017-2025 ($ MILLION)

FIGURE 15 GLOBAL PRESCRIBED CIC DRUGS MARKET 2017-2025 ($ MILLION)

FIGURE 16 GLOBAL OVER THE COUNTER CIC DRUG MARKET 2017-2025 ($ MILLION)

FIGURE 17 NORTH AMERICA CIC DRUGS MARKET 2017-2025 ($ MILLION)

FIGURE 18 US CIC MARKET, 2017-2025 ($ MILLION)

FIGURE 19 CANADA CIC MARKET 2017-2025 ($ MILLION)

FIGURE 20 EUROPE CIC DRUGS MARKET 2017-2025 ($ MILLION)

FIGURE 21 UK CIC DRUG MARKET 2017-2025 ($ MILLION)

FIGURE 22 GERMANY CIC DRUG MARKET, 2017-2025 $ MILLION)

FIGURE 23 REST OF EUROPE CIC DRUG MARKET 2017-2025 ($ MILLION)

FIGURE 24 ASIA PACIFIC CIC DRUG MARKET 2017-2025 ($ MILLION)

FIGURE 25 CHINA CIC DRUG MARKET 2017-2027 ($ MILLION)

FIGURE 26 COMPARISON OF PHARMACEUTICAL SALES ACROSS THE GLOBE

FIGURE 27 JAPAN CIC DRUG MARKET 2017-2025 ($ MILLION)

FIGURE 28 REST OF APAC CIC DRUG MARKET 2017-2025 ($ MILLION)

FIGURE 29 MIDDLE EAST & AFRICA CIC DRUGS MARKET 2017-2025 ($ MILLION)

FIGURE 30 LATIN AMERICA CIC DRUG MARKET 2017-2025 ($ MILLION)

Back to Top